AI in Drug Discovery Market to Hit USD 6.89 Billion by 2029

Rising Demand to Shorten Clinical Timelines and the Integration of Deep Learning in Oncology Drive an Explosive 29.9% CAGR in the Biopharma Sector
The global Artificial Intelligence (AI) in Drug Discovery Market [https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=Paidpr-k] is standing on the precipice of a transformative era. According to the latest strategic analysis by MarketsandMarkets, the market is expected to surge from USD 1.86 billion in 2024 to a staggering USD 6.89 billion by 2029.This rapid expansion, characterized by a Compound Annual Growth Rate (CAGR) of 29.9%, reflects a fundamental shift in how life sciences organizations approach the traditionally slow and expensive process of bringing new therapies to market. As pharmaceutical giants and agile biotech startups alike face the "Eroom's Law" phenomenon-where drug discovery becomes slower and more expensive over time-AI has emerged as the critical lever to reverse this trend.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=Paidpr-k]

Accelerating the "Hit-to-Lead" Journey

The research highlights that the Hit-to-lead Identification/Lead Generation segment held the largest market share in 2023, accounting for 29.2% of the total industry. This dominance is fueled by the widespread adoption of AI-driven virtual screening and predictive modeling. By evaluating massive chemical libraries in silico, these tools allow researchers to bypass months of manual "wet lab" experimentation, identifying viable lead compounds with unprecedented speed and precision.

Furthermore, De Novo Drug Design has emerged as a powerhouse use case, capturing 31.7% of the market share. Rather than simply searching through existing libraries, generative AI models are now capable of designing entirely new molecular structures optimized for specific biological targets, significantly reducing the reliance on legacy compound collections.

Oncology and Precision Medicine Take the Lead

The therapeutic landscape is currently dominated by Oncology. The high volume of genomic data and the desperate need for targeted cancer therapies make this field the primary testing ground for AI. Advanced machine learning tools are being utilized to identify novel biomarkers and predict patient-specific drug responses, moving the needle closer to the goal of true precision medicine.

Beyond cancer, the report identifies significant growth in:

*
Infectious Diseases: Rapid vaccine design and optimization.

*
Neurology: Understanding complex central nervous system (CNS) disorders.

*
Cardiovascular Diseases: Leveraging AI for better PK/PD (Pharmacokinetics/Pharmacodynamics) simulations.

The Role of "Star" Players and Technology Titans

The ecosystem is currently characterized by a mix of high-performance computing leaders and specialized AI-first biotech firms. NVIDIA Corporation (US) has been identified as a "Star" player, providing the GPU-accelerated frameworks necessary for large-scale molecular simulations. Similarly, Schrodinger, Inc. (US) and Insilico Medicine (US) continue to set the benchmark for end-to-end AI platforms that combine target discovery with clinical trial prediction.

The report also highlights the rise of Cloud-Based Deployment as the preferred model for the industry. The need for scalable computing power and seamless global collaboration has made cloud environments the backbone of modern R&D, allowing even smaller biotech firms access to world-class AI tools.

Challenges: Data Quality and the Human Factor

Despite the optimistic forecast, the path to 2029 is not without hurdles. The market faces a persistent shortage of an AI-skilled workforce capable of bridging the gap between data science and biology. Additionally, limited availability of high-quality, non-siloed datasets remains a significant challenge. Many valuable data points remain locked within the private archives of major pharmaceutical firms, hindering the training of more robust, "human-aware" AI systems.

Regulatory ambiguity also poses a risk. As agencies like the FDA continue to refine guidelines for AI-based medical software, developers must navigate a complex and evolving compliance landscape to prove the safety and efficacy of AI-derived clinical assets.

Request Sample Pages-https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=Paidpr-k]

Regional Outlook: North America Leads, Asia Pacific Accelerates

In 2023, North America held a commanding 44.8% revenue share, supported by a dense concentration of tech giants and pharmaceutical leaders. However, the Asia Pacific region is projected to be the fastest-growing market through 2029. This growth is driven by massive government investment in AI infrastructure in China, Japan, and India, coupled with a booming biotechnology sector eager to adopt cost-effective R&D solutions.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ai-in-drug-discovery-market-to-hit-usd-689-billion-by-2029]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.